Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorized
  2. c-icon icon-chevron-right
March 28, 2012

AMT reports positive data from Glybera study

Amsterdam Molecular Therapeutics (AMT) has announced the positive data from Glybera 14 week study demonstrating that one-time administration of the gene therapy Glybera (alipogene tiparvovec) is able to improve chylomicron (fat particles in the blood) metabolism following consumption of a low fat meal.

Amsterdam Molecular Therapeutics (AMT) has announced the positive data from a Glybera 14 week study, demonstrating that one-time administration of the gene therapy Glybera (alipogene tiparvovec) is able to improve chylomicron metabolism following consumption of a low fat meal.

Glybera introduces a normal, healthy LPL gene into the body so that it can make functional lipoprotein lipase (LPL) protein.

In an open label CT-AMT-011-02 clinical study, five lipoprotein lipase deficiency (LPLD) subjects in Quebec, Canada, were administered alipogene tiparvovec at a dose of 1 x 1012 genome copies per kg.

Following ingestion of a low fat meal, chylomicron metabolism, plasma palmitate and glycerol appearance rates were determined at two weeks before and 14 weeks after administration of alipogene tiparvovec.

The study showed that following administration of alipogene tiparvovec, the triglyceride (TG) content of the chylomicron fraction and the chylomicron-triglyceride (TG)/total plasma TG ratio were reduced throughout the postprandial period.

AMT chief medical officer Carlos Camozzi said the study provides additional, independent support on the ability of Glybera to restore chylomicron metabolism in LPLD patients.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

"We believe by restoring the body’s ability to metabolise these particles in LPLD patients, Glybera treatment results in fewer pancreatitis attacks," Camozzi added.

Glybera has been evaluated in three interventional clinical studies which demonstrated that fat concentrations in blood were reduced after therapy in nearly all patients between three and 12 weeks after injection of Glybera.

Dr. André Carpentier, Division of Endocrinology at the Université de Sherbrooke, Quebec, Canada, said the data showed that Glybera has an impact on chylomicron metabolism 14 weeks after a single administration.

"Although the patient cohort is small, due to the rare nature of LPLD, these results are very encouraging. LPLD patients often suffer from extremely painful bouts of pancreatitis, which is believed to be caused by the accumulation of chylomicron particles in the blood," Carpentier added.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU